Woburn, Mass. – July 19, 2022 − Aphios Corporation is pleased to announce today that its Founder and CEO, Dr. Trevor P. Castor will present its double-encapsulated mRNA vaccine to sustain efficacy over a longer period of time, decrease dosing regimen and improve room temperature stability at the 15th Annual Bioprocessing Summit, Boston, MA. https://tinyurl.com/ua7dvpfu.
For more than a decade, the Bioprocessing Summit has been recognized as the premier forum for industry leaders to share the latest research in bioprocess R&D, scale-up, quality and analytics. The 15th Annual Bioprocessing Summit will cover seven streams from upstream to downstream processing including one on Vaccine Development and Manufacturing, and mRNA Based Therapies. Vaccines and mRNA-based therapies have gained a lot of attention recently due to COVID-19. The Vaccine & mRNA Therapies stream will explore the technical challenges facing the formulation, development, characterization, manufacturing, and supply of next-generation vaccines, mRNA vaccines, mRNA gene therapies, RNAi, and gene therapies.
This Vaccine & mRNA Therapies stream is broken down into two tracts. The Vaccine Development and Manufacturing track tackles the practical challenges facing the development, manufacturing, and characterization of vaccine therapies. Topics including manufacturing at the global scale, CMC (Chemistry, Manufacturing and Controls) under accelerated timelines, utilizing new technologies, ensuring product quality, formulation, delivery, and managing complex supply chains will be covered. The mRNA-Based Therapies track will explore the technical challenges facing the manufacture and purification, formulation, development, scale-up, and supply of next-generation mRNA vaccines and therapies.
Aphios will present in the mRNA-Based Therapies track. Aphios is developing a single-shot, room temperature stable mRNA vaccine by double nanoencapsulating the mRNA construct in lipid nanoparticles or phospholipid nanosomes and biodegradable polymer nanospheres. We are using continuous flow, solvent-free processes that minimize loss of potency, preserve antigenicity of the nanoencapsulated mRNA and eliminate residual organic solvents. The impact of this development would be significant to the US and worldwide vaccination for current and future coronavirus pandemics and other infectious diseases.
About Aphios Corporation:
Aphios (www.aphios.com) is a clinical stage, green biotechnology company developing enabling technology platforms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, Aphios is developing enhanced therapeutics to prevent disease, maintain health, improve quality-of-life and treat chronic diseases including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19, and central and peripheral nervous system disorders in an environmentally sustainable manner.
Research reported in this press release was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R43AI165352. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.